Picture of Idorsia logo

IDIA Idorsia Share Price

0.000.00%
ch flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m+39.69%
3m-2.13%
6m-41.22%
1yr-82.78%
Volume Change (%)
10d/3m-2.13%
Price vs... (%)
52w High-80.15%
50d MA+22.78%
200d MA-37.75%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-98.4%
Return on Equityn/a
Operating Margin-182.23%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Idorsia EPS forecast chart

Profile Summary

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Directors

Last Annual
December 31st, 2022
Last Interim
September 30th, 2023
Incorporated
March 3rd, 2017
Public Since
June 16th, 2017
No. of Employees
636
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
ch flag iconSIX Swiss Exchange
Shares in Issue
178,920,816

IDIA Share Price Performance

Upcoming Events for IDIA

Q1 2024 Idorsia Ltd Earnings Release

Full Year 2023 Idorsia Ltd Earnings Release

Idorsia Ltd Annual Shareholders Meeting

Idorsia Ltd Annual Shareholders Meeting

Half Year 2024 Idorsia Ltd Earnings Release

Similar to IDIA

Picture of Addex Therapeutics logo

Addex Therapeutics

ch flag iconSIX Swiss Exchange

Picture of BACHEM HOLDING AG logo

BACHEM HOLDING AG

ch flag iconSIX Swiss Exchange

Picture of BB Biotech AG logo

BB Biotech AG

ch flag iconSIX Swiss Exchange

FAQ